To see all protocols that comply with the WHO Essential Medicine List 
  1. Home
  2. Cancer genetics
  3. Adult
  4. Risk management

CDKN2A – risk management

On this page
Expand all Collapse all Back to top

Familial melanoma due to a heritable pathogenic variant in the CDKN2A gene is an autosomal dominant condition, strongly modified by polygenic and environmental risk factors.

This risk management guideline has been developed for individuals who have NOT been diagnosed with a relevant cancer/tumour. The care of affected individuals should be individualised based on their clinical situation, and the monitoring they need as part of their treatment and post-treatment follow up. However, management of the risk of new primary melanoma is in most cases their most important ongoing melanoma-related health issue.

The risk management of an individual with a pathogenic variant in two or more genes that confer a predisposition to cancer should also be individualised.

  • Known carrier of a pathogenic variant in the CDKN2A gene. 
  • 50% risk of being a pathogenic variant carrier.

Exclusion criteria

  • Individuals in families with a pathogenic variant in other cancer predisposition genes associated with increased risks of melanoma. 
  • Individuals from families meeting familial melanoma diagnostic criteria where testing has not been done or where no pathogenic variant has been identified. Link to familial melanoma referral criteria
Cancer CDKN2A pathogenic variant carrier General population by age 80 yrs* 
Melanoma 52% by age 80 yrsr 4.9%**
Pancreatic Uncertain but increased in some populations rr 1.18%

*Figures from Australian Institute of Health and Welfare (AIHW) 2018. Australian Cancer Incidence and Mortality (ACIM) books. 2015 data.
**In Australia population melanoma risk varies by state (higher in QLD and WA).

Cancer type Recommendations***
Melanoma
Surveillance Age to begin Strategy and frequency

From 18 years of age
  • Monthly self examination of skin.
  • Initial fundoscopy to exclude coincidental uveal naevi.
  • 6 monthly specialist dermatological total body skin examination, including scalp and genitalia, supported by total body dermoscopy and total body photography.
Pancreatic Surveillance There is no evidence to support a benefit from screening. Screening should only be undertaken as part of a clinical trial.

 ***the impact of lifestyle on general cancer risks should be discussed e.g. exercise regularly, maintain a healthy weight, have a healthy diet, limit alcohol intake, do not smoke and avoid excessive sun exposure.

Follow population guidelines to avoid excessive sun exposure and sunburn, including:
  • wear protective clothing when UV levels high (UV index ≥ 3)
  • use sunscreen that provides UVA and UVB protection and has a SPF of 30 or greater (UV index ≥ 3)
  • avoid vitamin D deficiency
  • solariums (tanning beds) should not be used 
  • do not smoke

See also Cancer Council Australia SunSmart Position statements

Several observational studies have demonstrated lower Breslow depth and lower risk of advanced or fatal melanoma in screen detected melanomas using either monthly self-examination or regular clinical examination of skin. Specificity of screening is higher with clinical rather than self-examination and improves with increased clinician training. A recent German study reported a 47% decrease in melanoma mortality in a screened population at average risk.r

Australian studies have shown that six-monthly specialist skin examination, supported by dermoscopy and total body photography, is effective in reducing thickness of prospectively detected melanomas, and in reducing the number of ineffectual skin lesion excisions in those at very high risk of melanoma (CDKN2A pathogenic variant carriers or equivalent).r The intervention was also cost-effective compared with current practice.r

Not smoking is recommended because pancreatic cancer has a known association with smoking and there are reports of an increased risk of smoking-related head-and-neck cancers in CDKN2A pathogenic variant positive families.r

Sixth monthly surveillance is recommended for CDKN2A pathogenic variant carriers because of evidence of cost effectiveness in the Australian setting.r 

Relatives who are non-carriers of an identified familial CDKN2A pathogenic variant have a higher risk of cutaneous melanoma than the general population (but lower than carrier relatives). This is probably explained by inheritance of other less penetrant melanoma susceptibility genes combined with shared environmental risks among family members. Less frequent (annual) melanoma surveillance may still be warranted for non-carrier relatives. (Link to Alfred Health - Melanoma risk calculator for health professionals. Link to QIMR Berghofer - Melanoma Risk Predictor)

First degree blood relatives (parents/brothers/sisters/children) are at 50% risk of having inherited the pathogenic variant.  First degree relatives should be referred to a local clinical genetics service or familial cancer centre and dermatologist for comprehensive risk melanoma assessment. 

Link to information sheet on Informing family members about hereditary cancer.

[%id%]
[%title%]
[%abstract%]

Version 4

Date Summary of changes
4/10/2019

Protocol reviewed at May 2019 reference committee meeting. Discussions continued over email. Protocol approved for publication with the following changes made:

  • Summary: updated
  • Lifetime risk of cancer table: general population data updated
  • Cancer risk management guidelines: recommendations updated to align with recent data/publications
  • Evidence for risk management guidelines: updated to align with recent data/publications. Link to melanoma risk calculators added
  • References: new references added
  • New template changes applied
  • "Mutation" changed to "pathogenic variant" throughout document for consistency among eviQ cancer genetics protocols per agreement among the cancer genetics reference committees' chairs. Definition of "pathogenic variant" added as a pop-up.

Protocol version number increased to V.4. Review in 2 years

Version 3

Date Summary of changes
30/11/2016

New protocol discussed at October 2015 and March 2016 cancer genetics reference committee meeting. Approved and published on eviQ. Next review in 2 years.
31/05/2017 Transferred to new eviQ website. Version changed to V.2.
28/08/2019 Protocol title changed from 'Risk management for a CDKN2A mutation carrier' to 'CDKN2A – risk management' in accordance with Cancer Genetics Reference Committees' consensus. Version number increased to V.3.

The information contained in this document is based on the highest level of available evidence and consensus of the eviQ reference committee regarding their views of currently accepted approaches to care or treatment. Any clinician seeking to apply or consult this document is expected to use independent clinical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use is subject to eviQ’s disclaimer available at www.eviQ.org.au

Send feedback for this page

First approved:
Last reviewed:
Review due:

The currency of this information is guaranteed only up until the date of printing, for any updates please check:

https://www.eviq.org.au/p/1516

31 May 2020